'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Drug Discovery Today

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.drudis.2008.10.011PMID 19049901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular similarity measures.

  2011cited by this paper
• A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology

  2008cited by this paper
• Generation of a set of simple, interpretable ADMET rules of thumb.

  2008cited by this paper
• The impact of natural products upon modern drug discovery.

  2008cited by this paper
• Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?

  2008cited by this paper
• Human metabolic network reconstruction and its impact on drug discovery and development.

  2008cited by this paper
• Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.

  2008cited by this paper
• Informatics and computational strategies for the study of lipids.

  2008cited by this paper
• The growing scope of applications of genome-scale metabolic reconstructions using Escherichia coli

  2008cited by this paper
• Facilitating the development of controlled vocabularies for metabolomics technologies with text mining

  2008cited by this paper
• Evolution of Mammals and Their Gut Microbes

  2008cited by this paper
• The Edinburgh human metabolic network reconstruction and its functional analysis

  2007cited by this paper
• Global reconstruction of the human metabolic network based on genomic and bibliomic data

  2007cited by this paper
• Drug discovery beyond the 'rule-of-five'.

  2007cited by this paper
• The influence of drug-like concepts on decision-making in medicinal chemistry

  2007cited by this paper
• Closed-loop, multiobjective optimization of two-dimensional gas chromatography/mass spectrometry for serum metabolomics.

  2007cited by this paper
• Exploitation of bile acid transport systems in prodrug design.

  2007cited by this paper
• Comparing the chemical spaces of metabolites and available chemicals: models of metabolite-likeness

  2007cited by this paper
• Structure-based maximal affinity model predicts small-molecule druggability

  2007cited by this paper
• Fragment-based approaches to enzyme inhibition.

  2007cited by this paper
• The role of molecular size in ligand efficiency.

  2007cited by this paper
• Informatics and modeling challenges in fragment-based drug discovery.

  2007cited by this paper
• The virtual human: Towards a global systems biology of multiscale, distributed biochemical network models

  2007cited by this paper
• KEGG for linking genomes to life and the environment

  2007cited by this paper
• HMDB: the Human Metabolome Database

  2007cited by this paper
• Exploiting protein structure data to explore the evolution of protein function and biological complexity

  2006cited by this paper
• Systems biology, metabolic modelling and metabolomics in drug discovery and development.

  2006cited by this paper
• Can we rationally design promiscuous drugs?

  2006cited by this paper
• Global mapping of pharmacological space

  2006cited by this paper
• Cheminformatics analysis and learning in a data pipelining environment

  2006cited by this paper
• XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification.

  2006cited by this paper
• The application of systems biology to drug discovery.

  2006cited by this paper
• A Simple Approach for Indexing the Oral Druglikeness of a Compound: Discriminating Druglike Compounds from Nondruglike Ones

  2006cited by this paper
• Comparative QSAR- and Fragments Distribution Analysis of Drugs, Druglikes, Metabolic Substances, and Antimicrobial Compounds

  2006cited by this paper
• A bioinformatician's view of the metabolome.

  2006cited by this paper
• Metabolomics, modelling and machine learning in systems biology – towards an understanding of the languages of cells

  2006cited by this paper
• A simple approach for indexing the oral druglikeness of a compound: discriminating druglike compounds from nondruglike ones.

  2006cited by this paper
• The role of blood-brain barrier studies in the pharmaceutical industry.

  2006cited by this paper
• MeMo: a hybrid SQL/XML approach to metabolomic data management for functional genomics

  2006cited by this paper
• Database resources of the National Center for Biotechnology Information

  2006cited by this paper
• The CATH domain structure database: new protocols and classification levels give a more comprehensive resource for exploring evolution

  2006cited by this paper
• In Silico Drug Discovery: Solving the “Target‐rich and Lead‐poor” Imbalance Using the Genome‐to‐drug‐lead Paradigm

  2006cited by this paper
• LMSD: LIPID MAPS structure database

  2006cited by this paper
• Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits.

  2006cited by this paper
• Chemical Tools for Indications Discovery

  2005cited by this paper
• Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition.

  2005cited by this paper
• From genomics to chemical genomics: new developments in KEGG

  2005cited by this paper
• ZINC - A Free Database of Commercially Available Compounds for Virtual Screening

  2005cited by this paper
• Lipid and non-lipid effects of statins.

  2005cited by this paper
• Pleiotropic effects of statins.

  2005cited by this paper
• Closed-loop, multiobjective optimization of analytical instrumentation: gas chromatography/time-of-flight mass spectrometry of the metabolomes of human serum and of yeast fermentations.

  2005cited by this paper
• Druggability indices for protein targets derived from NMR-based screening data.

  2005cited by this paper
• Ligand efficiency indices as guideposts for drug discovery.

  2005cited by this paper
• METLIN: A Metabolite Mass Spectral Database

  2005cited by this paper
• Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up

  2005cited by this paper
• Can cell systems biology rescue drug discovery?

  2005cited by this paper
• LMPD: LIPID MAPS proteome database

  2005cited by this paper
• A comprehensive classification system for lipids11 The evaluation of this manuscript was handled by the former Editor-in-Chief Trudy Forte. Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.E400004-JLR200

  2005cited by this paper
• Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates

  2005cited by this paper
• A comprehensive classification system for lipids 1

  2005cited by this paper
• Ligand efficiency: a useful metric for lead selection.

  2004cited by this paper
• The European Bioinformatics Institute's data resources: towards systems biology

  2004cited by this paper
• Fragment-based lead discovery

  2004cited by this paper
• Navigating chemical space for biology and medicine

  2004cited by this paper
• Transporter-mediated drug delivery: recent progress and experimental approaches.

  2004cited by this paper
• Increased acyclovir oral bioavailability via a bile acid conjugate.

  2004cited by this paper
• Drug-like Annotation and Duplicate Analysis of a 23-Supplier Chemical Database Totalling 2.7 Million Compounds

  2004cited by this paper
• A proposed framework for the description of plant metabolomics experiments and their results

  2004cited by this paper
• Pursuing the leadlikeness concept in pharmaceutical research.

  2004cited by this paper
• The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology

  2004cited by this paper
• Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures.

  2004cited by this paper
• Molecular similarity measures.

  2004cited by this paper
• A guide to drug discovery: Hit and lead generation: beyond high-throughput screening

  2003cited by this paper
• The lipid and non-lipid effects of statins.

  2003cited by this paper
• Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry

  2003cited by this paper
• Selection criteria for drug‐like compounds

  2003cited by this paper
• Nonleadlikeness and leadlikeness in biochemical screening.

  2003cited by this paper
• A structure-based anatomy of the E.coli metabolome.

  2003cited by this paper
• A 'rule of three' for fragment-based lead discovery?

  2003cited by this paper
• Grouping of coefficients for the calculation of inter-molecular similarity and dissimilarity using 2D fragment bit-strings.

  2002cited by this paper
• Molecular properties that influence the oral bioavailability of drug candidates.

  2002cited by this paper
• The druggable genome

  2002cited by this paper
• Predicting drug-likeness: why and how?

  2002cited by this paper
• Prediction of 'drug-likeness'.

  2002cited by this paper
• Cluster Analysis

  2002cited by this paper
• Reoptimization of MDL Keys for Use in Drug Discovery

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• Is There a Difference between Leads and Drugs? A Historical Perspective

  2001cited by this paper
• ADMET—turning chemicals into drugs

  2001cited by this paper
• Database Organization and Searching with E-State Indices

  2001cited by this paper
• Pleiotropic effects of statins

  2000cited by this paper
• Drug-like properties and the causes of poor solubility and poor permeability.

  2000cited by this paper
• Potential Drugs and Nondrugs: Prediction and Identification of Important Structural Features

  2000cited by this paper
• Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.

  2000cited by this paper
• The E-State as the Basis for Molecular Structure Space Definition and Structure Similarity

  2000cited by this paper
• Combination of molecular similarity measures using data fusion

  2000cited by this paper
• Improving the Odds in Discriminating "Drug-like" from "Non Drug-like" Compounds

  2000cited by this paper
• Biological simulations in drug discovery.

  1999cited by this paper
• On the Properties of Bit String-Based Measures of Chemical Similarity

  1998cited by this paper
• Identification of Biological Activity Profiles Using Substructural Analysis and Genetic Algorithms

  1998cited by this paper

• Black Gold in Medicine: Rediscovering the Pharmacological Potential

  2026cites this paper
• BGC-MAC and BGC-MAP: Attention-Based Models for Biosynthetic Gene Cluster Classification and Product Matching

  2025cites this paper
• Identification of natural product-based drug combination (NPDC) using artificial intelligence.

  2025cites this paper
• Obtain substance of anti-glioblastoma from Erigeron breviscapus through fragment-based target research (FBTR): An efficient strategy for pharmacology investigation and optimization of natural products

  2025cites this paper
• Screening of Potential Drug Targets Based on the Genome-Scale Metabolic Network Model of Vibrio parahaemolyticus

  2025cites this paper
• Phenotypic Screening for Targeted Protein Degradation: Strategies, Challenges, and Emerging Opportunities.

  2025cites this paper
• A Direct Relationship Between ‘Blood Stasis’ and Fibrinaloid Microclots in Chronic, Inflammatory, and Vascular Diseases, and Some Traditional Natural Products Approaches to Treatment

  2025cites this paper
• Monoamine oxidase and neurodegeneration: mechanisms, inhibitors and natural compounds for therapeutic intervention.

  2024cites this paper
• Myofibrillogenesis Regulator‐1 Regulates the Ubiquitin Lysosomal Pathway of Notch3 Intracellular Domain Through E3 Ubiquitin‐Protein Ligase Itchy Homolog in the Metastasis of Non‐Small Cell Lung Cancer

  2024cites this paper
• Synthesis of Metabolites and Metabolite-like Compounds Using Biocatalytic Systems

  2023cites this paper
• Analysis of metabolites in human gut: illuminating the design of gut-targeted drugs

  2023cites this paper
• Artificial intelligence for natural product drug discovery

  2023cites this paper
• Challenges in natural product-based drug discovery assisted with in silico-based methods

  2023cites this paper
• Deoxyguanosine-Linked Bifunctional Inhibitor of SAMHD1 dNTPase Activity and Nucleic Acid Binding

  2023cites this paper
• Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma

  2023influential citation
• Study on endogenous inhibitors against PD-L1: cAMP as a potential candidate

  2022cites this paper
• The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells

  2021cites this paper
• Drug metabolism and pharmacokinetic diversity of Taxus medicinal compounds

  2021cites this paper
• A Comprehensive Analysis into the Therapeutic Application of Natural Products as SIRT6 Modulators in Alzheimer’s Disease, Aging, Cancer, Inflammation, and Diabetes

  2021cites this paper
• Natural product drug discovery in the artificial intelligence era

  2021cites this paper
• Commercial SARS-CoV-2 Targeted, Protease Inhibitor Focused and Protein–Protein Interaction Inhibitor Focused Molecular Libraries for Virtual Screening and Drug Design

  2021cites this paper
• Are we out of the infancy of microalgae-based drug discovery?

  2021cites this paper
• Weak Microbial Metabolites: a Treasure Trove for Using Biomimicry to Discover and Optimize Drugs

  2020cites this paper
• Proposed Multi-linear Regression Model to Identify Cyclooxygenase-2 Selective Active Pharmaceutical Ingredients

  2020cites this paper
• New Molecular Screening Approach for Discovery of Novel CycloOxygenase-2 Inhibitors through Multi Linear Regression Models

  2020cites this paper
• Proposed Multi-linear Regression Model to Identify Cyclooxygenase-2 Selective Active Pharmaceutical Ingredients

  2020influential citation
• Natural Products as Modulators of Sirtuins

  2020cites this paper
• Microbiome Metabolite Mimics Accelerate Drug Discovery.

  2020cites this paper
• Phytochemical conjugation as a potential semisynthetic approach toward reactive and reuse of obsolete sulfonamides against pathogenic bacteria

  2020cites this paper
• Structural Similarities between Some Common Fluorophores Used in Biology, Marketed Drugs, Endogenous Metabolites, and Natural Products

  2019cites this paper
• Fundamental physical and chemical concepts behind “drug-likeness” and “natural product-likeness”

  2019cites this paper
• Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma

  2019cites this paper
• Generation of a Small Library of Natural Products Designed to Cover Chemical Space Inexpensively

  2019cites this paper
• An integrative machine learning approach for prediction of toxicity-related drug safety

  2018cites this paper
• Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts.

  2018cites this paper
• From Food for Survival to Food for Personalized Optimal Health: A Historical Perspective of How Food and Nutrition Gave Rise to Nutrigenomics

  2018cites this paper
• YaTCM: Yet another Traditional Chinese Medicine Database for Drug Discovery

  2018cites this paper
• The expected characteristics of an in vitro human Blood Brain Barrier model derived from cell lines, for studying how ABC transporters influence drug permeability

  2018cites this paper
• Consensus rank orderings of molecular fingerprints illustrate the ‘most genuine’ similarities between marketed drugs and small endogenous human metabolites, but highlight exogenous natural products as the most important ‘natural’ drug transporter substrates

  2017cites this paper
• Computational and Experimental Approaches in Multi-Target Pharmacology

  2017cites this paper
• Drug repositioning for enzyme modulator based on human metabolite-likeness

  2017cites this paper
• Analysis of drug–endogenous human metabolite similarities in terms of their maximum common substructures

  2017cites this paper
• Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine

  2017cites this paper
• Open chemoinformatic resources to explore the structure, properties and chemical space of molecules

  2017cites this paper
• Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening.

  2017cites this paper
• NMD SERVER: NATURAL MEDICINES DATABASE FOR DRUG DISCOVERY

  2017cites this paper
• A novel anti-mitotic activity on human cells by Pulchelloid A, a compound isolated from the prairie plant Gaillardia aristata

  2017cites this paper
• Bioactive interactions in food and natural extracts

  2017cites this paper
• Human microbial metabolites as a source of new drugs.

  2016cites this paper
• MetMaxStruct: A Tversky-Similarity-Based Strategy for Analysing the (Sub)Structural Similarities of Drugs and Endogenous Metabolites

  2016cites this paper
• Low potency toxins reveal dense interaction networks in metabolism

  2016cites this paper
• Modelling Cellular Permeability via Carrier Mediated Transport

  2016influential citation
• The metabolome 18 years on: a concept comes of age

  2016cites this paper
• A systems approach to traditional oriental medicine

  2015cites this paper
• cis-Peptide Bonds: A Key for Intestinal Permeability of Peptides? .

  2015cites this paper
• Natural Products as Promising Therapeutics for Treatment of Influenza Disease.

  2015cites this paper
• Getting across the cell membrane: an overview for small molecules, peptides, and proteins.

  2015cites this paper
• Membrane transporter engineering in industrial biotechnology and whole cell biocatalysis.

  2015cites this paper
• A reliable computational workflow for the selection of optimal screening libraries

  2015cites this paper
• What would be the observable consequences if phospholipid bilayer diffusion of drugs into cells is negligible?

  2015cites this paper
• A Mini-review on Chemoinformatics Approaches for Drug Discovery

  2015cites this paper
• The transporter-mediated cellular uptake of pharmaceutical drugs is based on their metabolite-likeness and not on their bulk biophysical properties: Towards a systems pharmacology ☆

  2015cites this paper
• Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolites

  2015cites this paper
• Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently

  2014cites this paper
• Alternative Models in Drug Discovery and Development Part I: In Silico and In Vitro Models

  2014cites this paper
• Investigating host-pathogen behavior and their interaction using genome-scale metabolic network models.

  2014cites this paper
• How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion

  2014cites this paper
• Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery☆

  2014cites this paper
• High-resolution mass spectrometry associated with data mining tools for the detection of pollutants and chemical characterization of honey samples.

  2014cites this paper
• A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs

  2014influential citation
• Cofactor-Independent Phosphoglycerate Mutase from Nematodes Has Limited Druggability, as Revealed by Two High-Throughput Screens

  2014cites this paper
• Coping with Combinatorial Space in Molecular Design

  2013cites this paper
• Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it

  2013cites this paper
• System to store DNA physical properties profiles with application to the promoters of Escherichia coli

  2013cites this paper
• Applications of genome-scale metabolic network models in the biopharmaceutical industry

  2013cites this paper
• The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so.

  2013cites this paper
• High‐Throughput and ‐Content Screening/Screening for New Pharmaceutics

  2013cites this paper
• The Microbiome as a Therapeutic Target for Metabolic Diseases

  2013cites this paper
• An analysis of a ‘community-driven’ reconstruction of the human metabolic network

  2013cites this paper
• Bioinformatic methods for species-specific metabolome inference

  2013influential citation
• The Impact of Natural Products Upon Cancer Chemotherapy

  2013cites this paper
• Metabolite concentration as a criterion for antibacterial discovery.

  2013cites this paper
• Exploring the Biologically Relevant Chemical Space for Drug Discovery

  2013cites this paper
• The Acid/Base Profile of the Human Metabolome and Natural Products

  2013cites this paper
• How Do Metabolites Differ from Their Parent Molecules and How Are They Excreted?

  2013cites this paper
• A comparative analysis of the molecular topologies for drugs, clinical candidates, natural products, human metabolites and general bioactive compounds

  2012cites this paper
• Novel computational approaches to polypharmacology as a means to define responses to individual drugs.

  2012cites this paper
• Natural product-likeness score revisited: an open-source, open-data implementation

  2012cites this paper
• Evidence-based approach to assess passive diffusion and carrier-mediated drug transport.

  2012cites this paper
• NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database

  2012cites this paper
• Metabolic network modeling and simulation for drug targeting and discovery

  2012cites this paper
• Going further than Lipinski's rule in drug design

  2012cites this paper
• Toward in silico structure-based ADMET prediction in drug discovery.

  2012cites this paper
• Molecular property filters describing pharmacokinetics and drug binding.

  2012cites this paper
• Scientific discovery as a combinatorial optimisation problem: How best to navigate the landscape of possible experiments?

  2012cites this paper
• A metabolic network approach for the identification and prioritization of antimicrobial drug targets.

  2012cites this paper
• Recent trends and observations in the design of high-quality screening collections.

  2011cites this paper
• The Interweaving of Cheminformatics and HTS.

  2011cites this paper
• Structural diversity of biologically interesting datasets: a scaffold analysis approach

  2011cites this paper
• Understanding and Classifying Metabolite Space and Metabolite-Likeness

  2011influential citation